183 related articles for article (PubMed ID: 32450054)
21. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Shah M; Sachdeva M; Dodiuk-Gad RP
Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251
[No Abstract] [Full Text] [Related]
22. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Humphrey LL
Ann Intern Med; 2020 Sep; 173(5):W88-W89. PubMed ID: 32730105
[No Abstract] [Full Text] [Related]
23. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC
Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396
[No Abstract] [Full Text] [Related]
24. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
Gao J; Hu S
Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
[TBL] [Abstract][Full Text] [Related]
25. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Principi N; Esposito S
Lancet Infect Dis; 2020 Oct; 20(10):1118. PubMed ID: 32311322
[No Abstract] [Full Text] [Related]
26. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.
Martinez Navarro W; Ly L; Segal MS; Shukla AM
Asia Pac J Ophthalmol (Phila); 2020; 9(4):374-375. PubMed ID: 32740071
[No Abstract] [Full Text] [Related]
27. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
Ingraham NE; Boulware D; Sparks MA; Schacker T; Benson B; Sparks JA; Murray T; Connett J; Chipman JG; Charles A; Tignanelli CJ
Crit Care; 2020 Apr; 24(1):182. PubMed ID: 32345336
[No Abstract] [Full Text] [Related]
28. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.
Mazzitelli M; Davoli C; Scaglione V; Fusco P; La Gamba V; Matera G; Trecarichi EM; Torti C
Travel Med Infect Dis; 2020; 37():101826. PubMed ID: 32739472
[No Abstract] [Full Text] [Related]
29. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
Islam M
J Coll Physicians Surg Pak; 2020 Jun; 30(6):78. PubMed ID: 32723461
[No Abstract] [Full Text] [Related]
30. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Mehta S; Bhandari S; Mehta S
J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
[TBL] [Abstract][Full Text] [Related]
31. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
Guzman-Prado Y
Am J Cardiol; 2020 Sep; 130():162-163. PubMed ID: 32624192
[No Abstract] [Full Text] [Related]
32. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
Arnold SLM; Buckner F
Clin Transl Sci; 2020 Jul; 13(4):642-645. PubMed ID: 32268005
[No Abstract] [Full Text] [Related]
33. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
34. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?
Pagliano P; Piazza O; De Caro F; Ascione T; Filippelli A
Clin Infect Dis; 2020 Jul; 71(15):887-888. PubMed ID: 32211764
[No Abstract] [Full Text] [Related]
35. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
Frigerio M
Int J Cardiol; 2020 Oct; 316():285-286. PubMed ID: 32473921
[No Abstract] [Full Text] [Related]
36. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
Grandolfo M; Romita P; Bonamonte D; Cazzato G; Hansel K; Stingeni L; Conforti C; Giuffrida R; Foti C
Dermatol Ther; 2020 Jul; 33(4):e13499. PubMed ID: 32362051
[No Abstract] [Full Text] [Related]
37. [Cardiovascular safety of hydroxychloroquine in the COVID-19 pandemic].
Bozzo R; Ibelli F; Scublinsky D
Medicina (B Aires); 2020; 80 Suppl 3():89-90. PubMed ID: 32658855
[No Abstract] [Full Text] [Related]
38. RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS".
Peiffer-Smadja N; Costagliola D
Am J Epidemiol; 2020 Nov; 189(11):1443-1444. PubMed ID: 32685975
[No Abstract] [Full Text] [Related]
39. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.
Joob B; Wiwanitkit V
J Rheumatol; 2020 Oct; 47(10):1587. PubMed ID: 32451353
[No Abstract] [Full Text] [Related]
40. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm.
DeJong C; Wachter RM
JAMA Intern Med; 2020 Aug; 180(8):1118-1119. PubMed ID: 32347894
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
